Regeneron Pharmaceuticals, Inc. (REGN)

Regeneron Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Operating Revenue	13,606	13,687	12,581	11,808	15,791	7,940
Other Revenue	480	515	536.1	365.1	281.2	557
Revenue	14,086	14,202	13,117	12,173	16,072	8,497
Revenue Growth (YoY)	7.52%	8.27%	7.76%	-24.26%	89.14%	29.58%
Cost of Revenue	7,212	7,103	6,255	5,153	5,298	3,767
Gross Profit	6,874	7,100	6,862	7,020	10,774	4,730
Selling, General & Admin	2,898	2,954	2,631	2,116	1,825	1,346
Other Operating Expenses	-	-	-2.1	-89.9	-45.6	-280.4
Operating Expenses	2,898	2,954	2,629	2,026	1,779	1,066
Operating Income	3,975	4,145	4,233	4,994	8,995	3,665
Interest Expense	-47.8	-55.2	-73	-59.4	-57.3	-56.9
Interest & Investment Income	723.4	711.4	495.9	160.1	45.8	75.4
Currency Exchange Gain (Loss)	-0.5	-0.5	-12.9	50.2	0.4	-
Other Non Operating Income (Expenses)	24.5	15.8	-20	8.8	4	19.3
EBT Excluding Unusual Items	4,675	4,817	4,623	5,154	8,988	3,702
Gain (Loss) on Sale of Investments	453.6	117.7	-237.8	-39.8	386.1	196
Other Unusual Items	-38.1	-53.4	-	-	-	-
Pretax Income	4,984	4,780	4,199	4,859	9,326	3,810
Income Tax Expense	484.9	367.3	245.7	520.4	1,251	297.2
Net Income	4,499	4,413	3,954	4,338	8,075	3,513
Net Income to Common	4,499	4,413	3,954	4,338	8,075	3,513
Net Income Growth	16.63%	11.61%	-8.87%	-46.28%	129.86%	66.05%
Shares Outstanding (Basic)	108	108	107	107	106	108
Shares Outstanding (Diluted)	114	115	114	114	112	115
Shares Change (YoY)	0.13%	1.23%	0.18%	1.16%	-2.52%	0.44%
EPS (Basic)	41.81	40.90	37.05	40.51	76.40	32.65
EPS (Diluted)	39.43	38.34	34.77	38.22	71.97	30.52
EPS Growth	16.49%	10.27%	-9.03%	-46.89%	135.81%	65.33%
Free Cash Flow	3,102	3,665	3,875	4,425	6,529	2,004
Free Cash Flow Per Share	27.18	31.84	34.08	38.98	58.19	17.41
Gross Margin	48.80%	49.99%	52.32%	57.67%	67.04%	55.67%
Operating Margin	28.22%	29.19%	32.27%	41.03%	55.97%	43.13%
Profit Margin	31.94%	31.07%	30.14%	35.64%	50.24%	41.35%
Free Cash Flow Margin	22.02%	25.80%	29.54%	36.35%	40.63%	23.58%
EBITDA	4,471	4,628	4,654	5,335	9,281	3,901
EBITDA Margin	31.74%	32.59%	35.48%	43.83%	57.75%	45.90%
D&A For EBITDA	495.7	482.9	421	341.4	286.2	235.9
EBIT	3,975	4,145	4,233	4,994	8,995	3,665
EBIT Margin	28.22%	29.19%	32.27%	41.03%	55.97%	43.13%
Effective Tax Rate	9.73%	7.68%	5.85%	10.71%	13.41%	7.80%
Revenue as Reported	14,086	14,202	13,117	12,173	16,072	8,497

Updated Apr 29, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q